World Malaria Day: Zika virus against malaria, malaria drug lupus and malaria vaccine

World Malaria Day: Zika virus against malaria, malaria drug lupus and malaria vaccine ;

World Malaria Day is April 25, and the theme this year is to end malaria forever. This year, however, a new threat has emerged known as Zika virus, another mosquito-borne disease. In light of the increase of this virus, it is important that you educate yourself as malaria and Zika, and how is the disease can affect conditions such as metabolic syndrome and lupus. It is important to note that people with certain health conditions may not benefit from anti-malarial drugs.

These are the stories of Bel Marra Health on malaria, malaria vaccines, the Zika virus, and other associated conditions.

virus Zika and malaria are mosquito-borne diseases, and because the increase Zika for the first time in Brazil and now abroad, many are questioning the similarities and differences between malaria and Zika virus.

Zika is becoming a growing problem because it is not only affecting the population of Brazil, but sending researchers and scientists around the world in a frenzy to better understand the virus and develop appropriate treatments and potentially a cure.

Malaria, however, has been living in Africa for decades, and there are effective treatment methods available to deal with the disease.

Although both Zika virus and malaria are transmitted by mosquitoes, the two diseases still have their respective differences, which is important to understand. Here is a breakdown of the similarities and differences when it comes to Zika virus and malaria. Continue reading …

Metabolic syndrome in women with lupus affecting antimalarial drugs can be avoided. A recent study found that a drug against malaria could be effective in the prevention of metabolic syndrome in women with lupus. Metabolic syndrome is classified by the National Heart, Lung and Blood as “a group of risk factors that increase the risk of heart disease and other health problems such as diabetes and stroke.”

The study, led by Luciana F. Muniz, evaluated the frequency of metabolic syndrome and disease in relation to 103 patients with lupus premenopausal women, along with 35 healthy premenopausal women control.

The metabolic syndrome was higher among women with lupus compared with healthy women. The researchers also found that the use of chloroquine – an antimalarial drug – had a protective effect against metabolic syndrome in patients with lupus. Continue reading …

Displays a drug currently being tested promise as a cure for malaria. Researchers at UT Southwestern Medical Center and researchers in Australia are working together in this potential cure.
Malaria is transmitted by mosquitoes. It causes fever, chills, flu-like symptoms, and – in severe cases – death. Mosquitoes spread a parasite that attacks red blood cells. It can also be transmitted through blood transfusion committed, although this is very rare. According to the Centers for Disease Control and Prevention, malaria killed about 500,000 people in 2013. Most of these deaths were children in Africa.

The CDC said about 1,500 cases of malaria reported in the US every year. Patients are usually visitors or travelers from sub-Saharan Africa and Asia. The drug being tested works DSM265 killing malaria parasites resistant to drugs. The Plasmodium parasite is directed, and so far the drug has shown promise in preclinical studies.

the need for a new drug to combat malaria is high, as more cases of malaria resistant to treatment are reported.

“The problem is that we are starting to see more drug resistance, and this is what has carried out all antimalarials we’ve had,” said Dr. Margaret Phillips, professor of pharmacology at UT Southwestern. Continue reading …

one week (17 July 2015) Bel Marra Health ago reported on a drug currently being developed by researchers at UT Southwestern Medical Center and researchers in australia, showing promise as a cure for malaria.

On the heels of that report comes a possible malaria vaccine.

The Committee for Medicinal Products for Human Use (CHMP), a division of the European Medicines Agency (EMA), worked closely with other experts from the World Health Organization (WHO) and regulators of relevant countries before adopting a positive scientific opinion Mosquirix, a vaccine against Plasmodium falciparum and hepatitis B.

the newly developed vaccine is intended for active immunization of children from six weeks to 17 months against malaria in areas where malaria is regularly, and also for immunization against hepatitis B.

the Mosquirix malaria vaccine was submitted to the EMA to assess their quality, safety and effectiveness as well as its risk-benefit balance for markets outside the European Union. However, in its assessment, the CHMP apply the same stringent standards used for vaccines sold in the EU. Despite decades of research on malaria vaccines, Mosquirix is ​​the first malaria vaccine to be evaluated by a regulatory agency. Continue reading …

In the case of malaria research, “crime pays.” If all goes according to plan for researchers from the School of Medicine of Washington in St. Louis, the compound used in crime scenes to find traces of blood may one day be used to kill the malaria parasite
the new study fits perfectly in line with wHO guidelines, suggesting that artemisinin -. antimalarial drug most commonly used – can only be used in combination with other treatments because the parasite is becoming resistant to it.

The compound of luminol glows blue when it reacts with hemoglobin in red blood cells. Researchers have shown that they can use this gloss to trick malaria infected red blood cells in the construction of a volatile chemical arsenal.

To accomplish this, the researchers first gave the infected red blood cells an unusual amino acid and then the blue glow is used to activate the chemical. The strategy developed in killing the parasite.

According to the lead author, Daniel Goldberg, professor of medicine and molecular microbiology, blue light emitted by the luminol is enhanced by the drug artemisinin malaria. The results show that we can combine these two agents to form an effective treatment against the malaria parasite.

The results of the study are available online in the journal eLife. Continue reading …

The post World Malaria Day: Zika virus against malaria, malaria drug lupus and malaria vaccine , appeared first on belmarrahealth here: Here

You May Also Like: